Exosomal miRNAs as biomarkers in predicting chemotherapy‑induced cardiotoxicity in patients with cancer (Review)
- Authors:
- Vedant Shah
- Viraj Panchal
- Abhi Shah
- Bhavya Vyas
- Subham Bhowmik
- Ishita Panchal
- Pragya Jain
-
Affiliations: Department of Internal Medicine, The New York Medical College Graduate Medical Education Program at St. Mary's General Hospital and Saint Clare's Health, Denville, NJ 07834, USA, Department of Medicine, Smt. N.H.L. Municipal Medical College and SVPISMR, Ahmedabad, Gujarat 380058, India, Department of Family Medicine, Hennepin Healthcare, Minneapolis, MN 55415, USA, Department of Neurology, Max Smart Hospital, New Delhi 110017, India, Department of Medicine, Jawaharlal Nehru Medical College, Belagavi, Karnataka 590010, India, Department of Internal Medicine, Baptist Hospital of Southeast Texas, Beaumont, TX 77701, USA - Published online on: September 4, 2025 https://doi.org/10.3892/mi.2025.268
- Article Number: 69
-
Copyright : © Shah et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Abstract
 |
|
Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, et al: Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 31:171–190. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Mudd TW Jr, Khalid M and Guddati AK: Cardiotoxicity of chemotherapy and targeted agents. Am J Cancer Res. 11:1132–1147. 2021.PubMed/NCBI | |
|
Batool SM, Yekula A, Khanna P, Hsia T, Gamblin AS, Ekanayake E, Escobedo AK, You DG, Castro CM, Im H, et al: The liquid biopsy consortium: Challenges and opportunities for early cancer detection and monitoring. Cell Rep Med. 4(101198)2023.PubMed/NCBI View Article : Google Scholar | |
|
Boen HM, Cherubin M, Franssen C, Gevaert AB, Witvrouwen I, Bosman M, Guns PJ, Heidbuchel H, Loeys B, Alaerts M, et al: Circulating MicroRNA as biomarkers of anthracycline-induced cardiotoxicity: JACC: Cardiooncology state-of-the-art review. JACC CardioOncol. 6:183–199. 2024.PubMed/NCBI View Article : Google Scholar | |
|
de Wall C, Bauersachs J and Berliner D: Cardiooncology-dealing with modern drug treatment, long-term complications, and cancer survivorship. Clin Exp Metastasis. 38:361–371. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Nagy A, Börzsei D, Hoffmann A, Török S, Veszelka M, Almási N, Varga C and Szabó R: A comprehensive overview on chemotherapy-induced cardiotoxicity: Insights into the underlying inflammatory and oxidative mechanisms. Cardiovasc Drugs Ther: Mar 16, 2024 (Epub ahead of print). | |
|
Berardi R, Caramanti M, Savini A, Chiorrini S, Pierantoni C, Onofri A, Ballatore Z, De Lisa M, Mazzanti P and Cascinu S: State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: A literature review. Crit Rev Oncol Hematol. 88:75–86. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Volkova M and Russell R III: Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment. Curr Cardiol Rev. 7:214–220. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Vejpongsa P and Yeh ETH: Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities. J Am Coll Cardiol. 64:938–945. 2014.PubMed/NCBI View Article : Google Scholar | |
|
McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM and Yellon DM: Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 31:63–75. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Kuo CL, Ponneri Babuharisankar A, Lin YC, Lien HW, Lo YK, Chou HY, Tangeda V, Cheng LC, Cheng AN and Lee AY: Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: Foe or friend? J Biomed Sci. 29(74)2022.PubMed/NCBI View Article : Google Scholar | |
|
Jiang H, Zuo J, Li B, Chen R, Luo K, Xiang X, Lu S, Huang C, Liu L, Tang J and Gao F: Drug-induced oxidative stress in cancer treatments: Angel or devil? Redox Biol. 63(102754)2023.PubMed/NCBI View Article : Google Scholar | |
|
Thavendiranathan P, Wintersperger BJ, Flamm SD and Marwick TH: Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: A systematic review. Circ Cardiovasc Imaging. 6:1080–1091. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Ezaz G, Long JB, Gross CP and Chen J: Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 3(e000472)2014.PubMed/NCBI View Article : Google Scholar | |
|
Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G, Goliasch G, Gisslinger H, Steger GG, Hejna M, et al: Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 101:1874–1880. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Cho WCS: Circulating MicroRNAs as minimally invasive biomarkers for cancer theragnosis and prognosis. Front Genet. 2(7)2011.PubMed/NCBI View Article : Google Scholar | |
|
Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primdal-Bengtson B, Dingli F, Loew D, Tkach M and Théry C: Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci USA. 113:E968–E977. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Gould SJ and Raposo G: As we wait: Coping with an imperfect nomenclature for extracellular vesicles. J Extracell Vesicles. 2(20389)2013.PubMed/NCBI View Article : Google Scholar | |
|
Mathivanan S, Ji H and Simpson RJ: Exosomes: Extracellular organelles important in intercellular communication. J Proteomics. 73:1907–1920. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ and Geuze HJ: B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 183:1161–1172. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 9:654–659. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Nolte-'t Hoen EN, Buermans HP, Waasdorp M, Stoorvogel W, Wauben MH and 't Hoen PA: Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. Nucleic Acids Res. 40:9272–9285. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Patel GK, Patton MC, Singh S, Khushman M and Singh AP: Pancreatic cancer exosomes: Shedding off for a meaningful journey. Pancreat Disord Ther. 6(e148)2016.PubMed/NCBI View Article : Google Scholar | |
|
Gajos-Michniewicz A, Duechler M and Czyz M: MiRNA in melanoma-derived exosomes. Cancer Lett. 347:29–37. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Azmi AS, Bao B and Sarkar FH: Exosomes in cancer development, metastasis, and drug resistance: A comprehensive review. Cancer Metastasis Rev. 32:623–642. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Riches A, Campbell E, Borger E and Powis S: Regulation of exosome release from mammary epithelial and breast cancer cells-a new regulatory pathway. Eur J Cancer. 50:1025–1034. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Suchorska WM and Lach MS: The role of exosomes in tumor progression and metastasis (review). Oncol Rep. 35:1237–1244. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Chen L, Guo P, He Y, Chen Z, Chen L, Luo Y, Qi L, Liu Y, Wu Q, Cui Y, et al: HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway. Cell Death Dis. 9(513)2018.PubMed/NCBI View Article : Google Scholar | |
|
Li Z, Yanfang W, Li J, Jiang P, Peng T, Chen K, Zhao X, Zhang Y, Zhen P, Zhu J and Li X: Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer. Cancer Lett. 432:237–250. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Demory Beckler M, Higginbotham JN, Franklin JL, Ham AJ, Halvey PJ, Imasuen IE, Whitwell C, Li M, Liebler DC and Coffey RJ: Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol Cell Proteomics. 12:343–355. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, et al: Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 26:707–721. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, Cheng HH, Arroyo JD, Meredith EK, Gallichotte EN, et al: Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci USA. 111:14888–14893. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, González S, Sánchez-Cabo F, González MÁ, Bernad A and Sánchez-Madrid F: Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun. 2(282)2011.PubMed/NCBI View Article : Google Scholar | |
|
Bland CL, Byrne-Hoffman CN, Fernandez A, Rellick SL, Deng W and Klinke DJ II: Exosomes derived from B16F0 melanoma cells alter the transcriptome of cytotoxic T cells that impacts mitochondrial respiration. FEBS J. 285:1033–1050. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Dioufa N, Clark AM, Ma B, Beckwitt CH and Wells A: Bi-directional exosome-driven intercommunication between the hepatic niche and cancer cells. Mol Cancer. 16(172)2017.PubMed/NCBI View Article : Google Scholar | |
|
Xu Z, Liu X, Wang H, Li J, Dai L, Li J and Dong C: Lung adenocarcinoma cell-derived exosomal miR-21 facilitates osteoclastogenesis. Gene. 666:116–122. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Yang H, Fu H, Wang B, Zhang X, Mao J, Li X, Wang M, Sun Z, Qian H and Xu W: Exosomal miR-423-5p targets SUFU to promote cancer growth and metastasis and serves as a novel marker for gastric cancer. Mol Carcinog. 57:1223–1236. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Gong L, Bao Q, Hu C, Wang J, Zhou Q, Wei L, Tong L, Zhang W and Shen Y: Exosomal miR-675 from metastatic osteosarcoma promotes cell migration and invasion by targeting CALN1. Biochem Biophys Res Commun. 500:170–176. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Bao L, You B, Shi S, Shan Y, Zhang Q, Yue H, Zhang J, Zhang W, Shi Y, Liu Y, et al: Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10. Oncogene. 37:2873–2889. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Street JM, Koritzinsky EH, Glispie DM, Star RA and Yuen PST: Urine exosomes: An emerging trove of biomarkers. Adv Clin Chem. 78:103–122. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Machida T, Tomofuji T, Ekuni D, Maruyama T, Yoneda T, Kawabata Y, Mizuno H, Miyai H, Kunitomo M and Morita M: MicroRNAs in salivary exosome as potential biomarkers of aging. Int J Mol Sci. 16:21294–21309. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Keller S, Rupp C, Stoeck A, Runz S, Fogel M, Lugert S, Hager HD, Abdel-Bakky MS, Gutwein P and Altevogt P: CD24 is a marker of exosomes secreted into urine and amniotic fluid. Kidney Int. 72:1095–1102. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Peng P, Yan Y and Keng S: Exosomes in the ascites of ovarian cancer patients: Origin and effects on anti-tumor immunity. Oncol Rep. 25:749–762. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Tanaka Y, Kamohara H, Kinoshita K, Kurashige J, Ishimoto T, Iwatsuki M, Watanabe M and Baba H: Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer. 119:1159–1167. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Wang H, Hou L, Li A, Duan Y, Gao H and Song X: Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int. 2014(864894)2014.PubMed/NCBI View Article : Google Scholar | |
|
Jain D, Russell RR, Schwartz RG, Panjrath GS and Aronow W: Cardiac complications of cancer therapy: Pathophysiology, identification, prevention, treatment, and future directions. Curr Cardiol Rep. 19(36)2017.PubMed/NCBI View Article : Google Scholar | |
|
Han X, Zhou Y and Liu W: Precision cardio-oncology: Understanding the cardiotoxicity of cancer therapy. NPJ Precis Oncol. 1(31)2017.PubMed/NCBI View Article : Google Scholar | |
|
Chang HM, Moudgil R, Scarabelli T, Okwuosa TM and Yeh ETH: Cardiovascular complications of cancer therapy: Best practices in diagnosis, prevention, and management: Part 1. J Am Coll Cardiol. 70:2536–2551. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Frères P, Bouznad N, Servais L, Josse C, Wenric S, Poncin A, Thiry J, Moonen M, Oury C, Lancellotti P, et al: Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer. 18(102)2018.PubMed/NCBI View Article : Google Scholar | |
|
Brabletz S and Brabletz T: The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer? EMBO Rep. 11:670–677. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Beji S, Milano G, Scopece A, Cicchillitti L, Cencioni C, Picozza M, D'Alessandra Y, Pizzolato S, Bertolotti M, Spaltro G, et al: Doxorubicin upregulates CXCR4 via miR-200c/ZEB1-dependent mechanism in human cardiac mesenchymal progenitor cells. Cell Death Dis. 8(e3020)2017.PubMed/NCBI View Article : Google Scholar | |
|
Damrot J, Nübel T, Epe B, Roos WP, Kaina B and Fritz G: Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br J Pharmacol. 149:988–997. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Magenta A, Cencioni C, Fasanaro P, Zaccagnini G, Greco S, Sarra-Ferraris G, Antonini A, Martelli F and Capogrossi MC: miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ. 18:1628–1639. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Potente M and Dimmeler S: Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle. 7:2117–2122. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Hu X, Liu H, Wang Z, Hu Z and Li L: miR-200a attenuated doxorubicin-induced cardiotoxicity through upregulation of Nrf2 in mice. Oxid Med Cell Longev. 2019(1512326)2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhang WC, Yang JH, Liu GH, Yang F, Gong JL, Jia MG, Zhang MJ and Zhao LS: miR-34b/c regulates doxorubicin-induced myocardial cell injury through ITCH. Cell Cycle. 18:3263–3274. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Vacchi-Suzzi C, Bauer Y, Berridge BR, Bongiovanni S, Gerrish K, Hamadeh HK, Letzkus M, Lyon J, Moggs J, Paules RS, et al: Perturbation of microRNAs in rat heart during chronic doxorubicin treatment. PLoS One. 7(e40395)2012.PubMed/NCBI View Article : Google Scholar | |
|
Zhu JN, Fu YH, Hu ZQ, Li WY, Tang CM, Fei HW, Yang H, Lin QX, Gou DM, Wu SL and Shan ZX: Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity. Sci Rep. 7(11879)2017.PubMed/NCBI View Article : Google Scholar | |
|
Zhou S, Chen HZ, Wan YZ, Zhang QJ, Wei YS, Huang S, Liu JJ, Lu YB, Zhang ZQ, Yang RF, et al: Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction. Circ Res. 109:639–648. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Bonfini L, Migliaccio E, Pelicci G, Lanfrancone L and Pelicci PG: Not all Shc's roads lead to Ras. Trends Biochem Sci. 21:257–261. 1996.PubMed/NCBI | |
|
Lacombe J and Zenhausern F: Emergence of miR-34a in radiation therapy. Crit Rev Oncol Hematol. 109:69–78. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Hu Y, Xia W and Hou M: Macrophage migration inhibitory factor serves a pivotal role in the regulation of radiation-induced cardiac senescencethrough rebalancing the microRNA-34a/sirtuin 1 signaling pathway. Int J Mol Med. 42:2849–2858. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Baban B, Liu JY, Qin X, Weintraub NL and Mozaffari MS: Upregulation of programmed death-1 and its ligand in cardiac injury models: Interaction with GADD153. PLoS One. 10(e0124059)2015.PubMed/NCBI View Article : Google Scholar | |
|
Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N and Honjo T: Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 291:319–322. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Tarrio ML, Grabie N, Bu DX, Sharpe AH and Lichtman AH: PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol. 188:4876–4884. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte MJ, Keir ME, Freeman GJ, Sharpe AH and Lichtman AH: Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation. 116:2062–2071. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, Smith S, Bader AG, Kim S and Hong DS: Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 35:180–188. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Ameres SL and Zamore PD: Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Neilsen CT, Goodall GJ and Bracken CP: IsomiRs-the overlooked repertoire in the dynamic microRNAome. Trends Genet. 28:544–549. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? Cell. 146:353–358. 2011.PubMed/NCBI View Article : Google Scholar | |
|
van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA and Olson EN: Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA. 105:13027–13032. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Roncarati R, Viviani Anselmi C, Losi MA, Papa L, Cavarretta E, Da Costa Martins P, Contaldi C, Saccani Jotti G, Franzone A, Galastri L, et al: Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 63:920–927. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Zile MR, Mehurg SM, Arroyo JE, Stroud RE, DeSantis SM and Spinale FG: Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet. 4:614–619. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Jing X, Yang J, Jiang L, Chen J and Wang H: MicroRNA-29b regulates the mitochondria-dependent apoptotic pathway by targeting Bax in doxorubicin cardiotoxicity. Cell Physiol Biochem. 48:692–704. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Leger KJ, Leonard D, Nielson D, de Lemos JA, Mammen PPA and Winick NJ: Circulating microRNAs: Potential markers of cardiotoxicity in children and young adults treated with anthracycline chemotherapy. J Am Heart Assoc. 6(e004653)2017.PubMed/NCBI View Article : Google Scholar | |
|
Liu Y, Taylor NE, Lu L, Usa K, Cowley AW Jr, Ferreri NR, Yeo NC and Liang M: Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension. 55:974–982. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, Manca V, Fabbi P, Ballestrero A, Brunelli C and Barsotti A: Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res. 69:736–745. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Kizaki K, Ito R, Okada M, Yoshioka K, Uchide T, Temma K, Mutoh K, Uechi M and Hara Y: Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice. Pharmacol Res. 53:341–346. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Eken SM, Christersdottir T, Winski G, Sangsuwan T, Jin H, Chernogubova E, Pirault J, Sun C, Simon N, Winter H, et al: MiR-29b mediates the chronic inflammatory response in radiotherapy-induced vascular disease. JACC Basic Transl Sci. 4:72–82. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Dinh TK, Fendler W, Chałubińska-Fendler J, Acharya SS, O'Leary C, Deraska PV, D'Andrea AD, Chowdhury D and Kozono D: Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer. Radiat Oncol. 11(61)2016.PubMed/NCBI View Article : Google Scholar | |
|
Lai L, Chen J, Wang N, Zhu G, Duan X and Ling F: MiRNA-30e mediated cardioprotection of ACE2 in rats with doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy. Life Sci. 169:69–75. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Zhou F, Lu X and Zhang X: Serum miR-30c level predicted cardiotoxicity in non-small cell lung cancer patients treated with bevacizumab. Cardiovasc Toxicol. 18:284–289. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Tong Z, Jiang B, Wu Y, Liu Y, Li Y, Gao M, Jiang Y, Lv Q and Xiao X: MiR-21 protected cardiomyocytes against doxorubicin-induced apoptosis by targeting BTG2. Int J Mol Sci. 16:14511–14525. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Yin C, Salloum FN and Kukreja RC: A novel role of microRNA in late preconditioning: upregulation of endothelial nitric oxide synthase and heat shock protein 70. Circ Res. 104:572–575. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X, Wang D, Krall TJ, Delphin ES and Zhang C: MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem. 284:29514–29525. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C, Gnyawali S, Shilo S, Nuovo GJ and Sen CK: MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res. 82:21–29. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, et al: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 456:980–984. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Viczenczova C, Szeiffova Bacova B, Egan Benova T, Kura B, Yin C, Weismann P, Kukreja R, Slezak J and Tribulova N: Myocardial connexin-43 and PKC signalling are involved in adaptation of the heart to irradiation-induced injury: Implication of miR-1 and miR-21. Gen Physiol Biophys. 35:215–222. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Kopcalic K, Petrovic N, Stanojkovic TP, Stankovic V, Bukumiric Z, Roganovic J, Malisic E and Nikitovic M: Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study. Pathol Res Pract. 215:626–631. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Xi J, Huang Q, Wang L, Ma X, Deng Q, Kumar M, Zhou Z, Li L, Zeng Z, Young KH, et al: miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. Oncogene. 37:3151–3165. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Loot AE and Fleming I: Cytochrome P450-derived epoxyeicosatrienoic acids and pulmonary hypertension: Central role of transient receptor potential C6 channels. J Cardiovasc Pharmacol. 57:140–147. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Zhao Y, Samal E and Srivastava D: Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 436:214–220. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL and Wang DZ: The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 38:228–233. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Shan ZX, Lin QX, Fu YH, Deng CY, Zhou ZL, Zhu JN, Liu XY, Zhang YY, Li Y, Lin SG and Yu XY: Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction. Biochem Biophys Res Commun. 381:597–601. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Tang Y, Zheng J, Sun Y, Wu Z, Liu Z and Huang G: MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int Heart J. 50:377–387. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Cheng Y, Tan N, Yang J, Liu X, Cao X, He P, Dong X, Qin S and Zhang C: A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci (Lond). 119:87–95. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Nishimura Y, Kondo C, Morikawa Y, Tonomura Y, Torii M, Yamate J and Uehara T: Plasma miR-208 as a useful biomarker for drug-induced cardiotoxicity in rats. J Appl Toxicol. 35:173–180. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H, Xiao J, Shan H, Wang Z and Yang B: The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci. 120:3045–3052. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y and Iwai N: Plasma miR-208 as a biomarker of myocardial injury. Clin Chem. 55:1944–1949. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Tony H, Yu K and Qiutang Z: MicroRNA-208a silencing attenuates doxorubicin induced myocyte apoptosis and cardiac dysfunction. Oxid Med Cell Longev. 2015(597032)2015.PubMed/NCBI View Article : Google Scholar | |
|
Desai VG, C*Kwekel J, Vijay V, Moland CL, Herman EH, Lee T, Han T, Lewis SM, Davis KJ, Muskhelishvili L, et al: Early biomarkers of doxorubicin-induced heart injury in a mouse model. Toxicol Appl Pharmacol. 281:221–229. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Wan Q, Xu T, Ding W, Zhang X, Ji X, Yu T, Yu W, Lin Z and Wang J: MiR-499-5p attenuates mitochondrial fission and cell apoptosis via p21 in doxorubicin cardiotoxicity. Front Genet. 9(734)2019.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Cheng Y, Yang J, Xu L and Zhang C: Cell-specific effects of miR-221/222 in vessels: Molecular mechanism and therapeutic application. J Mol Cell Cardiol. 52:245–255. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Watson CJ, Gupta SK, O'Connell E, Thum S, Glezeva N, Fendrich J, Gallagher J, Ledwidge M, Grote-Levi L, McDonald K and Thum T: MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail. 17:405–415. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Verjans R, Peters T, Beaumont FJ, van Leeuwen R, van Herwaarden T, Verhesen W, Munts C, Bijnen M, Henkens M, Diez J, et al: MicroRNA-221/222 family counteracts myocardial fibrosis in pressure overload-induced heart failure. Hypertension. 71:280–288. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Su M, Wang J, Wang C, Wang X, Dong W, Qiu W, Wang Y, Zhao X, Zou Y, Song L, et al: MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis. Cell Death Differ. 22:986–999. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Esplugas R, Arenas M, Serra N, Bellés M, Bonet M, Gascón M, Vallvé JC and Linares V: Effect of radiotherapy on the expression of cardiovascular disease-related miRNA-146a, -155, -221 and -222 in blood of women with breast cancer. PLoS One. 14(e0217443)2019.PubMed/NCBI View Article : Google Scholar | |
|
Tao L, Bei Y, Zhou Y, Xiao J and Li X: Non-coding RNAs in cardiac regeneration. Oncotarget. 6:42613–42622. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Feng B and Chakrabarti S: miR-320 regulates glucose-induced gene expression in diabetes. ISRN Endocrinol. 2012(549875)2012.PubMed/NCBI View Article : Google Scholar | |
|
Yin Z, Zhao Y, Li H, Yan M, Zhou L, Chen C and Wang DW: miR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway. Aging (Albany NY). 8:192–207. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Todorova VK, Makhoul I, Wei J and Klimberg VS: Circulating miRNA profiles of doxorubicin-induced cardiotoxicity in breast cancer patients. Ann Clin Lab Sci. 47:115–119. 2017.PubMed/NCBI | |
|
Totoń-Żurańska J, Sulicka-Grodzicka J, Seweryn MT, Pitera E, Kapusta P, Konieczny P, Drabik L, Kołton-Wróż M, Chyrchel B, Nowak E, et al: MicroRNA composition of plasma extracellular vesicles: A harbinger of late cardiotoxicity of doxorubicin. Mol Med. 28(156)2022.PubMed/NCBI View Article : Google Scholar | |
|
Pillai SS, Pereira DG, Bonsu G, Chaudhry H, Puri N, Lakhani HV, Tirona MT, Sodhi K and Thompson E: Biomarker panel for early screening of trastuzumab-induced cardiotoxicity among breast cancer patients in west virginia. Front Pharmacol. 13(953178)2022.PubMed/NCBI View Article : Google Scholar | |
|
Rigaud VOC, Ferreira LRP, Ayub-Ferreira SM, Ávila MS, Brandão SMG, Cruz FD, Santos MHH, Cruz CBBV, Alves MSL, Issa VS, et al: Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. Oncotarget. 8:6994–7002. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Gioffré S, Chiesa M, Cardinale DM, Ricci V, Vavassori C, Cipolla CM, Masson S, Sandri MT, Salvatici M, Ciceri F, et al: Circulating MicroRNAs as potential predictors of anthracycline-induced troponin elevation in breast cancer patients: Diverging effects of doxorubicin and epirubicin. J Clin Med. 9(1418)2020.PubMed/NCBI View Article : Google Scholar | |
|
Brown C, Mantzaris M, Nicolaou E, Karanasiou G, Papageorgiou E, Curigliano G, Cardinale D, Filippatos G, Memos N, Naka KK, et al: A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research. Cardiooncology. 8(16)2022.PubMed/NCBI View Article : Google Scholar | |
|
Zhang X, Sun Y, Zhang Y, Fang F, Liu J, Xia Y and Liu Y: Cardiac biomarkers for the detection and management of cancer therapy-related cardiovascular toxicity. J Cardiovasc Dev Dis. 9(372)2022.PubMed/NCBI View Article : Google Scholar | |
|
Hendrix A and Hume AN: Exosome signaling in mammary gland development and cancer. Int J Dev Biol. 55:879–887. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Galindo-Hernandez O, Villegas-Comonfort S, Candanedo F, González-Vázquez MC, Chavez-Ocaña S, Jimenez-Villanueva X, Sierra-Martinez M and Salazar EP: Elevated concentration of microvesicles isolated from peripheral blood in breast cancer patients. Arch Med Res. 44:208–214. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Webber J, Steadman R, Mason MD, Tabi Z and Clayton A: Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 70:9621–9630. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Kosgodage US, Mould R, Henley AB, Nunn AV, Guy GW, Thomas EL, Inal JM, Bell JD and Lange S: Cannabidiol (CBD) is a novel inhibitor for exosome and microvesicle (EMV) release in cancer. Front Pharmacol. 9(889)2018.PubMed/NCBI View Article : Google Scholar | |
|
Im EJ, Lee CH, Moon PG, Rangaswamy GG, Lee B, Lee JM, Lee JC, Jee JG, Bae JS, Kwon TK, et al: Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. Nat Commun. 10(1387)2019.PubMed/NCBI View Article : Google Scholar | |
|
Aoki N, Jin-no S, Nakagawa Y, Asai N, Arakawa E, Tamura N, Tamura T and Matsuda T: Identification and characterization of microvesicles secreted by 3T3-L1 adipocytes: redox- and hormone-dependent induction of milk fat globule-epidermal growth factor 8-associated microvesicles. Endocrinology. 148:3850–3862. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Müller G, Schneider M, Biemer-Daub G and Wied S: Microvesicles released from rat adipocytes and harboring glycosylphosphatidylinositol-anchored proteins transfer RNA stimulating lipid synthesis. Cell Signal. 23:1207–1223. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Konoshenko MY, Lekchnov EA, Vlassov AV and Laktionov PP: Isolation of extracellular vesicles: General methodologies and latest trends. Biomed Res Int. 2018(8545347)2018.PubMed/NCBI View Article : Google Scholar | |
|
Gardiner C, Di Vizio D, Sahoo S, Théry C, Witwer KW, Wauben M and Hill AF: Techniques used for the isolation and characterization of extracellular vesicles: Results of a worldwide survey. J Extracell Vesicles. 5(32945)2016.PubMed/NCBI View Article : Google Scholar | |
|
Ludwig N, Razzo BM, Yerneni SS and Whiteside TL: Optimization of cell culture conditions for exosome isolation using mini-size exclusion chromatography (mini-SEC). Exp Cell Res. 378:149–157. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhang H, Freitas D, Kim HS, Fabijanic K, Li Z, Chen H, Mark MT, Molina H, Martin AB, Bojmar L, et al: Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat Cell Biol. 20:332–343. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Sluijter JPG, Davidson SM, Boulanger CM, Buzás EI, de Kleijn DPV, Engel FB, Giricz Z, Hausenloy DJ, Kishore R, Lecour S, et al: Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position paper from the working group on cellular biology of the heart of the european society of cardiology. Cardiovasc Res. 114:19–34. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Ardekani AM and Naeini MM: The role of MicroRNAs in human diseases. Avicenna J Med Biotechnol. 2:161–179. 2010.PubMed/NCBI | |
|
Brandão-Lima PN, de Carvalho GB, Payolla TB, Sarti FM and Rogero MM: Circulating microRNA related to cardiometabolic risk factors for metabolic syndrome: A systematic review. Metabolites. 12(1044)2022.PubMed/NCBI View Article : Google Scholar | |
|
Tijsen AJ, Pinto YM and Creemers EE: Non-cardiomyocyte microRNAs in heart failure. Cardiovasc Res. 93:573–582. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Subbaswamy A and Saria S: From development to deployment: Dataset shift, causality, and shift-stable models in health AI. Biostatistics. 21:345–352. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Rulten SL, Grose RP, Gatz SA, Jones JL and Cameron AJM: The future of precision oncology. Int J Mol Sci. 24(12613)2023.PubMed/NCBI View Article : Google Scholar | |
|
Pellegrini L, Sileno S, D'Agostino M, Foglio E, Florio MC, Guzzanti V, Russo MA, Limana F and Magenta A: MicroRNAs in cancer treatment-induced cardiotoxicity. Cancers (Basel). 12(704)2020.PubMed/NCBI View Article : Google Scholar | |
|
Chang WT, Liu CF, Feng YH, Liao CT, Wang JJ, Chen ZC, Lee HC and Shih JY: An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline. Arch Toxicol. 96:2731–2737. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, et al: Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 122:1630–1637. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Jopling CL: Targeting microRNA-122 to treat hepatitis C virus infection. Viruses. 2:1382–1393. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Xu K, Chen C, Wu Y, Wu M and Lin L: Advances in miR-132-based biomarker and therapeutic potential in the cardiovascular system. Front Pharmacol. 12(751487)2021.PubMed/NCBI View Article : Google Scholar | |
|
Machida T, Tomofuji T, Maruyama T, Yoneda T, Ekuni D, Azuma T, Miyai H, Mizuno H, Kato H, Tsutsumi K, et al: miR-1246 and miR-4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer. Oncol Rep. 36:2375–2381. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Sun J, Aswath K, Schroeder SG, Lippolis JD, Reinhardt TA and Sonstegard TS: MicroRNA expression profiles of bovine milk exosomes in response to Staphylococcus aureus infection. BMC Genomics. 16(806)2015.PubMed/NCBI View Article : Google Scholar |
